Interní Med. 2016; 18(1): 14-18 | DOI: 10.36290/int.2016.004

What news brought last year on oral antidiabetic drugs?

MUDr. Jiří Slíva, Ph.D.1, prof. MUDr. Štěpán Svačina, DrSc.2
1 Ústav farmakologie 3. LF UK, Praha
2 III. interní klinika 1. LF UK a VFN Praha

The progress in the treatment of diabetes mellitus during last decade has been unprecedented, especially in the field of new oral antidiabetics. A high evidence of their effectiveness is needed for their successful clinical use as well as the evidence of their safety. In accordance to regulations of EMA and FDA, their cardiovascular safety has to be newly proven. Hence, the article summarizes most recent information from this topic, which was extensively discussed during last calendar year.

Keywords: antidiabetics, gliflozins, gliptins, diabetes mellitus, safety

Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J, Svačina Š. What news brought last year on oral antidiabetic drugs? Interní Med. 2016;18(1):14-18. doi: 10.36290/int.2016.004.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl.J Med 2013; 369: 1317-1326. Go to original source... Go to PubMed...
    2. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl. J Med 2013; 369: 1327-1335. Go to original source... Go to PubMed...
    3. Zannad F, Cannon CP, Cushman WC et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 385: 2067-2076. Go to original source... Go to PubMed...
    4. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl.J Med 2015; 373: 232-242. Go to original source... Go to PubMed...
    5. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl. J Med 2015; 373: 2247-2257. Go to original source... Go to PubMed...
    6. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl. J Med 2015; 373: 2117-2128. Go to original source... Go to PubMed...
    7. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl. J Med 2008; 358: 2545-2559. Go to original source...
    8. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl. J Med 2008; 358: 2560-2572. Go to original source...
    9. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl. J Med 2009; 360: 129-139. Go to original source... Go to PubMed...
    10. Wanner C. Central European & 5th Czech-Austrian Symposium on Nephrology. http://www.congress-live.eu/. 2015.
    11. Pevtzow L, Flapan D, Perojo F, Rotach D. The Year in Medicine 2015: News That Made a Difference. http://www.medscape.com/features/slideshow/public/year-in-medicine2015?nlid=92807_435&src=wnl_edit_medp_diab&uac=243329DN&spon=22&impID=914700&faf=1#page=9361(10), 1024-1025. 2015.
    12. Škrha J, Pelikánová T, Kvapil M. Doporučený postup péče o diabetes mellitus 2. typu. http://www.diab.cz/dokumenty/doporuceni_DM_2015-2_prezentace.pdf. 2016.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.